Press release
Emerging Trends Influencing The Growth Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Market: Innovative Antiemetic Solution Aims To Improve CINV Patient Outcomes
Chemotherapy-Induced Nausea and Vomiting (CINV)
How Big Is the Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size Expected to Be by 2034?
There has been a notable growth in the market size of chemotherapy-induced nausea and vomiting (CINV) in recent years. The market has the potential to expand from $2.92 billion in 2024 to $3.15 billion in 2025, suggesting a compound annual growth rate (CAGR) of 7.9%. This substantial increase in the historic period can be credited to factors such as expanded application of chemotherapy, enhancements in antiemetic agents, advanced clinical guidelines, and patient advocacy.
The market size for chemotherapy-induced nausea and vomiting (CINV) is projected to see robust expansion in the upcoming years, reaching $4.2 billion by 2029, with a compound annual growth rate (CAGR) of 7.5%. This surge in the predicted period can be owed to factors such as personalized medicine, progress in antiemetic agents, telehealth developments, remote monitoring, and initiatives related to health equity. Key trends for this forecast span include combined antiemetic treatments, supportive care services, digital health instruments, and survivorship care.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13031
What Are the Emerging Segments Within the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
The chemotherapy-induced nausea and vomiting (CINV) market covered in this report is segmented -
1) By Form: Injectables, Oral, Transdermal Patches
2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Class
3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)
4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores
5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications
Subsegments:
1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections
2) By Oral: Tablets, Capsules, Liquid Formulations
3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp
What Long-Term Drivers Are Shaping Chemotherapy-Induced Nausea and Vomiting (CINV) Market Trends?
The surge in cancer incidences is likely to fuel the growth of the market for chemotherapy-induced nausea and vomiting (CINV). Whenever cells in the body begin to uncontrollably multiply and spread throughout various regions, it's defined as cancer. As the number of cancer cases amplifies, the push towards creating more effective, specialized anti-emetic treatments to reduce CINV, a troubling by-product of chemotherapy, becomes more necessary. This increased emphasis on managing CINV has resulted in a better understanding of its primary causes and the development of breakthrough treatments. As cited by the American Cancer Society (ACS), a volunteer health organization devoted to eliminating cancer in the US, it's projected that in January 2023, there will be 1.9 million new cancer diagnoses (roughly 5,370 incidents per day) and 609,820 cancer-related deaths (approximately 1,670 fatalities daily). As such, the growing prevalence of cancer can be seen as a catalyst for the CINV market. The CINV market is also anticipated to grow due to positive regulatory provisions. Regulatory steps undertaken by governmental bodies for the establishment, application, or enforcement of rules can further enhance the prevention and management of CINV. Such initiatives are often geared towards the creation and enforcement of guidelines for CINV prevention and management. For example, as per the Food and Drug Administration, in 2023, the CDER (Center for Drug Evaluation and Research), a division under its umbrella, gave approval for 55 new drugs aimed at curbing CINV. Thus, the rise in supportive regulatory initiatives is facilitating the progression of the CINV market.
Who Are the Top Competitors in Key Chemotherapy-Induced Nausea and Vomiting (CINV) Market Segments?
Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.
What Are the Major Trends Shaping the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
Leading firms in the chemotherapy-induced nausea and vomiting (CINV) market are striving towards the creation of new product offerings like fixed intravenous antiemetic to gain a competitive edge. This type of antiemetic involves the delivery of a set dosage of medication via IV to prevent or manage nausea and vomiting, typically in post-surgery or chemotherapy settings. For instance, Glenmark Pharmaceuticals Limited, a pharmaceutical, generics, and over-the-counter (OTC) products manufacturer based in India, launched AKYNZEO I.V. in India in January 2023. This was the first-ever fixed intravenous antiemetic combination developed specifically to combat chemotherapy-induced nausea and vomiting (CINV). The product merges netupitant and palonosetron, aiming to address both instant and delayed bouts of nausea and vomiting. Apart from providing the convenience of a single dosage, it also elevates the complete response rates, thus improving the quality of life for individuals suffering from cancer. Clinical trials have indicated its specific advantages for patients undergoing highly emetogenic chemotherapy.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report
Which Regions Are Becoming Hubs for Chemotherapy-Induced Nausea and Vomiting (CINV) Market Innovation?
North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in chemotherapy-induced nausea and vomiting (CINV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
2. What is the CAGR expected in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
3. What Are the Key Innovations Transforming the Chemotherapy-Induced Nausea and Vomiting (CINV) Industry?
4. Which Region Is Leading the Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Emerging Trends Influencing The Growth Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Market: Innovative Antiemetic Solution Aims To Improve CINV Patient Outcomes here
News-ID: 4022108 • Views: …
More Releases from The Business Research Company
Bromine Derivatives Market to Grow at 7% CAGR, Reaching $6.92 Billion by 2029
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Bromine Derivatives Market Outlook: How is the Market Expected to Grow by 2025?
In the past few years, the size of the bromine derivatives market has been expanding consistently. We can expect the market value to rise from $5.09 billion in 2024 to $5.28 billion in 2025, reflecting a compound…
Purified Terephthalic Acid Industry to See Robust Expansion, Valued at $70.72 Bi …
Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments.
What Is the Projected CAGR for the Purified Terephthalic Acid Market from 2024 to 2025?
The market size for purified terephthalic acid has witnessed steady growth in recent years. It is expected to increase from $52.49 billion in 2024 to about $54.9 billion in 2025, experiencing a compound annual growth rate (CAGR)…
Basic Dyes Market Growth to be Driven by Emerging Trends | $2.26 Billion by 2029
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What is the Projected Market Size of the Basic Dyes Industry?
In the last few years, there has been a swift expansion in the size of the basic dyes market. It is projected to rise from $1.43 billion in 2024 to $1.59 billion in 2025 with a compound annual growth rate…
Pressure Sensitive Adhesive Tapes Market Size Forecast: $99.23 Billion by 2029 | …
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What Is the Projected Market Size Valuation of the Pressure Sensitive Adhesive Tapes Market by 2025?
In recent years, the market size of pressure sensitive adhesive tapes has expanded dramatically. It's predicted to rise from $69.98 billion in 2024 to $74.01 billion in 2025, with a compound annual growth rate (CAGR)…
More Releases for CINV
Key Influencer in the Chemotherapy-Induced Nausea and Vomiting (CINV) Market 202 …
How Are the key drivers contributing to the expansion of the chemotherapy-induced nausea and vomiting (cinv) market?
The escalating cases of cancer are expected to foster the expansion of the market for chemotherapy-induced nausea and vomiting (CINV). This rise is due to the uncontrolled development and spread of cancer cells in the body. As cancer prevalence increases, there's an increased drive to produce highly effective and specific anti-emetic treatments, which would…
Advancements and Trends in the Global Chemotherapy-induced Nausea and Vomiting ( …
Introduction:
The realm of cancer treatment is a dynamic arena where advancements continuously unfold. Among the multitude of challenges that cancer patients face, chemotherapy-induced nausea and vomiting (CINV) is a formidable adversary. In this article, we delve into the intricate landscape of the CINV market, exploring its evolution, current state, and future prospects.
Understanding CINV:
CINV, an acronym that echoes the discomfort experienced by countless individuals, stands for chemotherapy-induced nausea and vomiting. This…
CINV Existing and Pipeline Drugs Market: Rising Demand for CINV Drugs Owing to I …
CINV drugs are administered to patients suffering from vomiting and nausea that occurs as a side effect of chemotherapy. CINV can hinder the progress of patients undergoing chemotherapy, making it very crucial for oncologists to prescribe the right kind of CINV drugs to alleviate the discomfort. Delayed CINV and acute CINV are the two major subtypes of this condition. While the former occurs up to five days after treatment, the…
CINV Existing and Pipeline Drugs Market : Growing number of patients undergoing …
The growth of the global chemotherapy induced nausea and vomiting (CINV) market will be steered by the growing number of patients undergoing chemotherapy and a number of new drugs expected to be approved in the near future, says Transparency Market Research. In its report, titled “CINV Existing and Pipeline Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020,” the business intelligence firm says that…
Global Chemotheraphy Induced Nausea and Vomiting (CINV) Drugs Market Research Re …
This report studies Chemotheraphy Induced Nausea and Vomiting (CINV) Drugs in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering
GlaxoSmithKline Plc
Helsinn Group
Heron Therapeutics
Merck & Co Inc
Tesaro
...
Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of…
CINV Existing and Pipeline Drugs Market : Future Demand and Growth Analysis
Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV). CINV significantly affects the treatment of patients undergoing chemotherapy. Two major subtypes of CINV are acute CINV (occurs within 24 hours of chemotherapy) and delayed CINV (occurs between 24 hours and five days after treatment). Aloxi (palonosetron), Zofran generic (ondansetron), Kytril generic (granisetron), Emend…
